John Mitty Wednesday, May 8, 2013 |
Mary Ann Malack-Ragona Says Failed Clinical Trial Should Not Deter Researchers from Finding a Cure for Alzheimer’s Disease
Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer of the Alzheimer’s Disease Resource Center, Inc., says the failure of a potential treatment for Alzheimer’s Disease does not mean that the search for a cure is over, as many drug companies are diligently working on treatment to slow down or eradicate this disease.
On May 7, Baxter International announced that its drug, Gammagard, had failed to stop the decline of mental cognition caused by Alzheimer’s Disease in a late-stage clinical trial. The company said the drug, which is an immunoglobulin therapy, was unable to end the decline in either cognition or daily functioning when compared with a placebo.
The trial involved 390 patients with mild to moderate disease who were treated for 18 months. Baxter said the company would discontinue other trials testing the drug as a treatment for Alzheimer’s Disease.
“Every one of these clinical trials is significant because each trial provides additional information and insight, which can help in finding a cure for Alzheimer’s Disease,” Ms. Malack-Ragona said. “There are over 5 million people with a diagnosis of Alzheimer’s Disease, and 77 million baby boomers — 1 in 8 — are at risk for Alzheimer’s Disease. Alzheimer’s Disease Resource Center, Inc. provides care and support for individuals and families coping with the diagnosis of Alzheimer’s Disease and is working to fund local research to find a cure for Alzheimer’s Disease. The vision of Alzheimer’s Disease Resource Center is a future free from Alzheimer’s.”
For more information, call Ms. Malack-Ragona at (631) 820-8068 or visit www.adrcinc.org.
jmitty@longislandyellowpages.com Appears In: Press Releases
|